Marshall Wace LLP Invests $818,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)

Marshall Wace LLP acquired a new position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 59,303 shares of the biotechnology company's stock, valued at approximately $818,000. Marshall Wace LLP owned approximately 0.13% of Capricor Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Summit Investment Advisors Inc. increased its holdings in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 1,345 shares during the last quarter. Invesco Ltd. grew its holdings in Capricor Therapeutics by 20.5% during the 4th quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company's stock valued at $203,000 after buying an additional 2,500 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 2,947 shares during the last quarter. Corebridge Financial Inc. raised its holdings in shares of Capricor Therapeutics by 32.2% during the 4th quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company's stock worth $251,000 after acquiring an additional 4,434 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its position in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 5,000 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Stock Performance

NASDAQ CAPR traded down $0.14 on Tuesday, hitting $10.17. 236,331 shares of the stock were exchanged, compared to its average volume of 1,515,268. Capricor Therapeutics Inc has a 52-week low of $3.52 and a 52-week high of $23.40. The firm has a market capitalization of $464.31 million, a P/E ratio of -9.60 and a beta of 0.85. The stock has a fifty day moving average price of $11.75 and a two-hundred day moving average price of $14.52.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. The company had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Sell-side analysts expect that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CAPR. HC Wainwright restated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald restated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a report on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.